Cytokinetics‘ Aficamten Shows Promise in HCM Treatment

New data on Cytokinetics' aficamten, presented at the European Society of Cardiology Congress 2025, demonstrates its superiority over metoprolol in treating hypertrophic cardiomyopathy (HCM). Findings show improved cardiac structure and function, with a low incidence of atrial fibrillation. The FDA is reviewing aficamten's application.










